Just reported
From Biogen's results release of 28. Oktober 2026; its quarterly report has since been filed.
Actual
2,8B $
+11 % y/y
+2,5 % q/q
Guided
—
No guide given
Actual
-0,14 $
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Die Umsatzanteile sind Schätzungen für nine months ended September 30, 2026 und keine Zahlen aus einem eingereichten Bericht.
SPINRAZA
An injected medicine for spinal muscular atrophy, a disease that causes muscle weakness.
TYSABRI
An infusion medicine for relapsing multiple sclerosis.
LEQEMBI
An antibody medicine for early Alzheimer’s disease, developed and sold with Eisai.
SKYCLARYS
A medicine for Friedreich ataxia, an inherited disease that affects movement and coordination.
SYFOVRE
An eye injection for geographic atrophy, a disease that can cause central vision loss.
EMPAVELI
A medicine for a rare blood disorder and certain rare kidney diseases.
Biogen discovers, develops and sells medicines for neurological, immune-system and rare diseases. Its products include treatments for multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease and certain eye, kidney and blood disorders. It develops and commercializes some medicines with other drug companies, sharing costs, sales or profits under those agreements.
Gebaut aus den eigenen Einreichungen von Biogen Inc. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
The themes Biogen is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
253,51 $+1,2 %Schluss 13. Nov.
Zahlen bis 30. September 2026, aus dem 10-Q vom 28. Oktober 2026
Biogen sells prescription medicines for multiple sclerosis and rare diseases, including SPINRAZA for spinal muscular atrophy, through health-care providers.
Grade A
Das Band unter dem Kurs zeigt die Note an jedem Tag – gebildet nur aus den Unterlagen, die bis dahin veröffentlicht waren.
Zeigt 2 von 40 Quartalen der Notenhistorie von Biogen Inc.. Die übrigen 38 reichen zurück bis Oktober 2016.
